KR927003110A - 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 카메라 항체 - Google Patents
감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 카메라 항체 Download PDFInfo
- Publication number
- KR927003110A KR927003110A KR1019920701323A KR920701323A KR927003110A KR 927003110 A KR927003110 A KR 927003110A KR 1019920701323 A KR1019920701323 A KR 1019920701323A KR 920701323 A KR920701323 A KR 920701323A KR 927003110 A KR927003110 A KR 927003110A
- Authority
- KR
- South Korea
- Prior art keywords
- conjugate
- agent
- lesion
- radioisotope
- antibody
- Prior art date
Links
- 230000003902 lesion Effects 0.000 title claims description 14
- 230000002757 inflammatory effect Effects 0.000 title claims description 7
- 208000015181 infectious disease Diseases 0.000 title claims description 6
- 230000002458 infectious effect Effects 0.000 title claims description 6
- 239000004599 antimicrobial Substances 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 239000012216 imaging agent Substances 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 229940124597 therapeutic agent Drugs 0.000 claims 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 6
- 230000008685 targeting Effects 0.000 claims 6
- 239000003153 chemical reaction reagent Substances 0.000 claims 5
- 210000000265 leukocyte Anatomy 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 238000002059 diagnostic imaging Methods 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims 3
- 210000003714 granulocyte Anatomy 0.000 claims 3
- 229940126585 therapeutic drug Drugs 0.000 claims 3
- 239000012141 concentrate Substances 0.000 claims 2
- 239000003623 enhancer Substances 0.000 claims 2
- 238000002595 magnetic resonance imaging Methods 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 claims 1
- WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 229910052688 Gadolinium Inorganic materials 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 239000003096 antiparasitic agent Substances 0.000 claims 1
- 229940125687 antiparasitic agent Drugs 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- JCXGWMGPZLAOME-AKLPVKDBSA-N bismuth-212 Chemical compound [212Bi] JCXGWMGPZLAOME-AKLPVKDBSA-N 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- RYGMFSIKBFXOCR-AKLPVKDBSA-N copper-67 Chemical group [67Cu] RYGMFSIKBFXOCR-AKLPVKDBSA-N 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 229940072221 immunoglobulins Drugs 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- ZCYVEMRRCGMTRW-YPZZEJLDSA-N iodine-125 Chemical compound [125I] ZCYVEMRRCGMTRW-YPZZEJLDSA-N 0.000 claims 1
- 229940044173 iodine-125 Drugs 0.000 claims 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 claims 1
- 229910001437 manganese ion Inorganic materials 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 claims 1
- 230000001235 sensitizing effect Effects 0.000 claims 1
- 231100001274 therapeutic index Toxicity 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
- A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
- A61K51/1087—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin the immunoglobulin comprises domains from different animal species, e.g. chimeric immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
내용 없음
Description
감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 카메라 항체
[도면의 간단한 설명]
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (33)
- 과립구에 특이적으로 결합하는 항원-결합 초가변 영역과 인간 단핵리미포이드 세포상의 수용제에 대한 친화력이 높은 인간 면역 글로불린의 불변 영역을 함유하며, 적어도 하나의 진단시약 또는 치료약에 접합되어 있음을 특징으로 하는 백혈구 유착 병소를 타게팅하기 위한 카메라 항체-시약 접합체(chirneric antibody-agent conjugate).
- 제1항에 있어서, 상기 키메라는 진단용 영상화제(hnaging agent)에 결합되어 있음을 특징으로 하는 접합체.
- 제2항에 있어서, 상기 진단용 영상화제는 50∼500KeV범위의 감마선을 방출하는 방사성 동워원소 또는 양전자를 방출하는 방사성 동위원소임을 특징으로 하는 접합체.
- 제3항에 있어서, 상기 방사성 동위원소는 Tc-99m, I -123, Ga-67, In-111 또는 I -131임을 특징으로 하는 접합체.
- 제2항에 있어서, 상기 영상화제는 자기 공명 영상 증강제임을 특징으로 하는 접합체.
- 제5항에 있어서, 상기 시약은 가돌리늄 또는 망간 이온을 함유함을 특징으로 하는 접합체.
- 제1항에 있어서, 상기 초가변 영역이 Ia(DR)항원에 특이적으로 결합함을 특징으로 하는 접합체.
- 제1항에 있어서, 상기 키메라는 적어도 하나의 치료약에 접합되어 있음을 특징으로 하는 접합체.
- 제8항에 있어서, 상기 치료약은 방사성 동이원소임을 특징으로 하는 접합체.
- 제8항에 있어서, 상기 치료약은 항미생물제임을 특징으로 하는 접합체.
- 제8항에 있어서, 상기 치료약은 방사성 동위원소와 항미생물제의 조합임을 특징으로 하는 접합체.
- 제8항 내지 11항중 어느 한 항에 있어서, 상기 치료약은 중합체 담체를 이용하여 상기 키메라 항체에 접합되어 있음을 특징으로 하는 접합체.
- 제12항에 있어서, 상기 중합체는 덱스트란 또는 아미노텍스트란임을 특징으로 하는 접합체.
- 제10항, 12항 또는 13항에 있어서, 상기 항미생물제는 항균제임을 특징으로 하는 접합체.
- 제10항, 12항 또는 13항에 있어서, 상기 항미생물제는 항바이러스제임을 특징으로 하는 접합체.
- 제10항, 12항 또는 13항에 있어서, 상기 항미생물제는 항진균제임을 특징으로 하는 접합체.
- 제10항, 12항 또는 13항에 있어서, 상기 항미생물제는 항기생충제임을 특징으로 하는 접합체.
- 특허청구의 범위 제2항 내지 6항중 어느 한 항의 접합체를 타게팅에 유효한 양으로 포유동물에게 비경구적으로 투여함을 특징으로 하는 진단용 영상화제를 염증 또는 감영성 병변에 타게팅하는 방법.
- 제18항에 있어서, 상기 영상화재가 방사성 동위원소이고, 상기 병변부위에 접합체가 집중되기에 충분한 시간이 경과한 후 병변의 신틸레이션 그래프 영상을 얻음을 특징으로 하는 방법.
- 제18항에 있어서, 상기 영상화제가 자기공명 영상증강제이고, 상기 병변 부위에 접합체가 집중되기에 충분한 시간이 경과한 후 병변이 자기 공명 영상을 얻음을 특징으로 하는 방법.
- 타게텅 하기에 유효한 양의 접합체를 포유동물에게 비경구적으로 투여하여 치료약을 염증 또는 감염성 병변에 타게팅하는 방법에 사용하기 위한 시약의 제조에 사용됨을 특징으로 하는 특허청구의 범위 제8항 내지 17항중 어느 한 항에 따른 접합체의 용도.
- 제21항에 있어서, 키메라 항체의 초가변성 영역이 과립구의 1a(DR)항원에 특이적으로 결합합을 륵징으로 하는 용도.
- 제21항 또는 22항에 있어서, 상기 치료약은 방사성 동위원소임을 특징으로 하는 용도.
- 제23항에 있어서, 상기 방사성 동위원소는 구리-67, 요오드-125, 요오드-131, 레늄-186, 레늄-188, 비스무트-212 또는 아스타틴 211임을 특징으로 하는 용도.
- 제21항 또는 22항에 있어서, 상기 치료약은 항미생물제임을 특징으로 하는 용도.
- 제18항 내지 20항중 어느 한 항에 있어서, 접합체 투여후 상기 병변 부위에 있는 백혈구가 선택적으로 최대한의 접합체를 포획하기에 충분한 시간이 지난 후, 상기 접합체에 특이적으로 결합하는 비표지화원 이차항체 또는 항체 단편을 2∼72시간내에 상기 접합체의 집중화율을 적어도 약 20% 증가시키기에 충분한 양으로 피투여자에게 비경구적으로 투여하는 단계를 더 포함함을 특징으로 하는 방법.
- 제21항 내지 25항중 어느 한 항에 있어서, 상기 방범에 사용하기 위한 시약의 제조에 있어서 상기 키메라 접합체 이외에, 상기 접합체에 특이적으로 결합하는 비표지화된 이차 항체 또는 항체 단편을 사용하고, 또 상기 방법에 있어서 병변 부위에 있는 백혈구가 선택적으로 최대한의 집합체를 포획하기에 충분한 시간이 지난후, 상기 치료약의 치료지수를 적어도 약 10% 증가시키기에 충분한 양의 비표지화된 이차 항체 또는 항체 단편을 피투여자에게 이경구적으로 투여함을 특징으로 하는 용도.
- 제약학적으로 허용되는 멸균 주사 부형약에 용해시킨 특허청구의 범위 제1항 내지 17항중 어느 한 항의 접합체를 영상화 또는 치료에 유효한 양으로 함유함을 특징으로 하는, 백혈구를 함유하는 감염 또는 염증성 병변에 영상화제 또는 치료약을 타게팅시키기 위한 인체용의 멸균주사 제제.
- 적절한 용기에 담져 있는 특허청구의 범위 제1항 내지 17항중 어느 한 항의 적합체를 함유함을 특징으로 하는, 백혈구를 함유하는 감염 또는 염증성 병변을 생체내 검출 또는 치료하기 위한 용도에 적합한 키트.
- 제29항에 있어서, 제2용기에, 상기 접합체에 특이적으로 결합하는 비표지화 이차 항체 또는 항체 단편을 더 함유함을 특징으로 하는 키트.
- 타게팅 하기에 유효한 양의 접합체를 포유동물에게 경구적으로 투여하여 진단용 영상화제를 염증 또는 감염성 병변에 타게팅하는 방법에 사용하는 시약의 제조에 사용됨을 특징으로 하는 특허청구의 범위 제2항 내지 6항중 어느 한 항의 접합체의 용도.
- 제31항에 있어서, 키메라 항체의 초가변 영역이 과립구의 Ia(DR)항원에 특이적으로 결합함을 특징으로 하는 용도.
- 제21항에 있어서, 상기 방법에 사용하기 위한 시약의 제조에 있어서 상기 키메라 접합체 이의에, 상기 접합체에 특이적으로 결합하는 비표지화된 이차 항체 또는 항체 단편을 사용하고, 또 상기 방법에 있어서, 접합체 투여 병변부위에 있는 백혈구를 선택적으로 최대한의 접합체를 포획하기에 충분한 시간이 지난 후, 상기 비표지화된 이차 항체 또는 항체 단 단편을 2∼72시간이내에 상기 접합체의 집중화율을 적어도 약 20%증가시키기에 충분한 양으로 피투여자에게 비경구적으로 투여함을 특징으로 하는 용도.※ 참고사항:최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44654689A | 1989-12-05 | 1989-12-05 | |
US446,546 | 1989-12-05 | ||
PCT/US1990/006972 WO1991007987A1 (en) | 1989-12-05 | 1990-12-04 | Chimeric antibody for detection and therapy of infectious and inflammatory lesions |
Publications (2)
Publication Number | Publication Date |
---|---|
KR927003110A true KR927003110A (ko) | 1992-12-17 |
KR0162259B1 KR0162259B1 (ko) | 1998-12-01 |
Family
ID=23772990
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019920701323A KR0162259B1 (ko) | 1989-12-05 | 1990-10-04 | 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체 |
Country Status (13)
Country | Link |
---|---|
US (2) | US5637288A (ko) |
EP (1) | EP0434257B1 (ko) |
JP (1) | JP2810230B2 (ko) |
KR (1) | KR0162259B1 (ko) |
AT (1) | ATE100719T1 (ko) |
AU (1) | AU646658B2 (ko) |
CA (1) | CA2031129C (ko) |
DE (1) | DE69006337T2 (ko) |
ES (1) | ES2062418T3 (ko) |
IE (1) | IE65572B1 (ko) |
IL (1) | IL96534A (ko) |
WO (1) | WO1991007987A1 (ko) |
ZA (1) | ZA909719B (ko) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0495376B1 (en) * | 1991-01-15 | 1997-05-28 | Bayer Corporation | Cell surface receptor complimentation |
US6797492B2 (en) | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
AU2307092A (en) * | 1991-07-01 | 1993-02-11 | Mallinckrodt Medical, Inc. | Tissue specific imaging agents using internal image anti-idiotypic antibodies |
US6764681B2 (en) | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
US6086875A (en) * | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US6030613A (en) * | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
ITRM960808A1 (it) * | 1996-11-26 | 1998-05-26 | Rossolini Gianmaria | Immunoconiugati comprendenti anticorpi monoclonali umani o frammenti di essi per diagnosi in vivo e terapia |
ATE444082T1 (de) * | 2000-10-16 | 2009-10-15 | Cytoguide Aps | Funktion eines haptoglobin-hämoglobin-rezeptors und anwendungszwecke dafür |
DE60141773D1 (de) * | 2001-04-20 | 2010-05-20 | Inst Systems Biology | Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren |
US8703146B2 (en) * | 2001-04-20 | 2014-04-22 | Institute For Systems Biology | Toll-like receptor 5 ligands and methods of use |
EP1419236A4 (en) | 2001-07-24 | 2005-08-03 | Biogen Idec Inc | METHODS OF TREATING OR PREVENTING SCLEROSIS BY USE OF CD2-BINDING AGENTS |
US7591994B2 (en) | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
IL165669A0 (en) | 2002-07-29 | 2006-01-15 | Senomyx Inc | Identification of a novel bitter taste receptor t2r76 |
US7541440B2 (en) * | 2002-09-30 | 2009-06-02 | Immunomedics, Inc. | Chimeric, human and humanized anti-granulocyte antibodies and methods of use |
US7939304B2 (en) * | 2002-10-02 | 2011-05-10 | Catalyst Biosciences, Inc. | Mutant MT-SP1 proteases with altered substrate specificity or activity |
US20060024289A1 (en) * | 2002-10-02 | 2006-02-02 | Ruggles Sandra W | Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases |
US7651689B2 (en) * | 2002-11-15 | 2010-01-26 | Albert Einstein College Of Medicine Of Yeshiva University | Methods of applying ionization radiation for therapy of infections |
US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
US20050025763A1 (en) | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
WO2005060457A2 (en) | 2003-12-04 | 2005-07-07 | Pdl Biopharma, Inc. | Treatment of inflammatory bowel diseases with anti-ip-10 antibodies |
CN101501211A (zh) | 2004-03-31 | 2009-08-05 | 综合医院公司 | 测定癌症对表皮生长因子受体靶向性治疗反应性的方法 |
AU2005244271B2 (en) | 2004-04-12 | 2010-04-08 | Vertex Pharmaceuticals Incorporated | Cleavage of VEGF and VEGF receptor by wildtype and mutant MT-SP1 |
CA2565259A1 (en) | 2004-05-07 | 2005-12-08 | Astellas Us Llc | Soluble lfa-3 polypeptide for treating viral disorders |
US7973134B2 (en) * | 2004-07-07 | 2011-07-05 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways |
US20070166281A1 (en) * | 2004-08-21 | 2007-07-19 | Kosak Kenneth M | Chloroquine coupled antibodies and other proteins with methods for their synthesis |
US7935790B2 (en) * | 2004-10-04 | 2011-05-03 | Cell Singaling Technology, Inc. | Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways |
US7807789B2 (en) * | 2004-12-21 | 2010-10-05 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in EGFR-signaling pathways |
US20090099340A1 (en) * | 2007-10-12 | 2009-04-16 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
US20100151495A9 (en) * | 2005-08-31 | 2010-06-17 | Cell Signaling Technolgy, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
EP1934867A2 (en) * | 2005-08-31 | 2008-06-25 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in leukemia signaling pathways |
EP2674440B1 (en) | 2005-12-16 | 2019-07-03 | IBC Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
US20070186296A1 (en) * | 2006-02-02 | 2007-08-09 | Wyeth | Cloning, characterization, and application of tnfrsf19 in neurological disorders |
SG170091A1 (en) | 2006-03-10 | 2011-04-29 | Wyeth Corp | Anti-5t4 antibodies and uses thereof |
MX2008012023A (es) * | 2006-03-21 | 2008-10-01 | Wyeth Corp | Metodos para prevenir y tratar enfermedades amiloidogenicas. |
US20090298093A1 (en) * | 2006-04-27 | 2009-12-03 | Roberto Polakiewicz | Reagents for the Detection of Protein Phosphorylation in ATM & ATR Kinase Signaling Pathways |
WO2007146172A2 (en) | 2006-06-07 | 2007-12-21 | Bioalliance C.V. | Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same |
DK2046951T5 (da) | 2006-07-05 | 2012-01-23 | Catalyst Biosciences Inc | Proteasesreeningsmetoder og proteaser identificeret dermed |
US7939636B2 (en) * | 2006-08-11 | 2011-05-10 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in c-Src signaling pathways |
US20090258442A1 (en) * | 2006-08-31 | 2009-10-15 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
EP1972639A3 (en) | 2007-03-07 | 2008-12-03 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
EP1975184A3 (en) | 2007-03-26 | 2008-11-26 | Cell Signaling Technology, Inc. | Serine or threonine phosphorylation sites |
US20080238709A1 (en) * | 2007-03-28 | 2008-10-02 | Faramarz Vaziri | One-way communication apparatus with dynamic key generation |
EP1983003A3 (en) | 2007-04-19 | 2009-03-11 | Peter Hornbeck | Tyrosine phosphorylation sites and antibodies specific for them |
US7977462B2 (en) | 2007-04-19 | 2011-07-12 | Cell Signaling Technology, Inc. | Tyrosine phosphorylation sites |
EP1983002A3 (en) | 2007-04-19 | 2009-03-11 | Peter Hornbeck | Tyrosine phosphorylation sites and antibodies specific for them |
US20090053831A1 (en) | 2007-05-01 | 2009-02-26 | Cell Signaling Technology, Inc. | Tyrosine phosphorylation sites |
CA2697032C (en) | 2007-08-22 | 2021-09-14 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
EP2062920A3 (en) | 2007-11-21 | 2009-06-17 | Peter Hornbeck | Protein phosphorylation by basophilic serine/threonine kinases in insulin signalling pathways |
DK2245063T3 (en) | 2007-12-18 | 2015-12-07 | Bioalliance Cv | Antibodies that recognize carbohydrate AN EPITOPE ON CD-43 AND CEA expressed CANCER CELLS AND PRACTICES BY WHICH THEY USED |
US20090220991A1 (en) * | 2008-02-29 | 2009-09-03 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in leukemia signaling pathways |
EP2274437B1 (en) | 2008-04-10 | 2015-12-23 | Cell Signaling Technology, Inc. | Compositions and methods for detecting egfr mutations in cancer |
WO2010019656A1 (en) * | 2008-08-12 | 2010-02-18 | Wyeth | Humanized anti-rage antibody |
EP2385955B1 (en) | 2009-01-12 | 2020-08-12 | CytomX Therapeutics, Inc. | Modified antibody compositions, methods of making and using thereof |
DK3903829T3 (da) | 2009-02-13 | 2023-06-26 | Immunomedics Inc | Immunkonjugater med en intracellulær spaltelig binding |
WO2010096838A2 (en) * | 2009-02-23 | 2010-08-26 | Cytomx Therapeutics, Llc | Proproteins and methods of use thereof |
TW201125583A (en) * | 2009-12-23 | 2011-08-01 | Bioalliance Cv | Anti-EpCAM antibodies that induce apoptosis of cancer cells and methods using same |
EP2704751B1 (en) | 2011-05-02 | 2019-04-17 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
US9745631B2 (en) | 2011-12-20 | 2017-08-29 | Dana-Farber Cancer Institute, Inc. | Methods for diagnosing and treating oncogenic kras-associated cancer |
CA2874521A1 (en) | 2012-05-24 | 2013-11-28 | Dana-Farber Cancer Institute, Inc. | Targeting the glutamine to pyruvate pathway for treatment of oncogenic kras-associated cancer |
MX2014015205A (es) | 2012-06-14 | 2015-08-14 | Ambrx Inc | Anticuerpos anti-psma conjugados a polipeptidos de ligando de receptor nuclear. |
US20150285802A1 (en) | 2012-07-18 | 2015-10-08 | Dana-Farber Cancer Institute, Inc. | Methods for treating, preventing and predicting risk of developing breast cancer |
EP2895197B1 (en) | 2012-09-12 | 2020-02-26 | Ramot at Tel-Aviv University Ltd. | Immunoparticles and methods of generating and using same |
WO2015050844A1 (en) | 2013-10-01 | 2015-04-09 | Dana-Farber Cancer Institute, Inc. | Methods of treating cancer with atovaquone-related compounds |
US9139649B2 (en) | 2014-02-25 | 2015-09-22 | Immunomedics, Inc. | Humanized anti-CD22 antibody |
US10350264B2 (en) | 2014-03-27 | 2019-07-16 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating NCOA4-mediated autophagic targeting of ferritin |
EP3286224A4 (en) | 2015-04-22 | 2018-11-14 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells |
BR112018013912A2 (pt) | 2016-01-08 | 2018-12-18 | Bioalliance C.V. | anticorpos tetravalentes anti-psgl-1 e usos dos mesmos |
US11708421B2 (en) | 2016-07-18 | 2023-07-25 | Ramot At Tel-Aviv University Ltd. | Modular platform for targeted therapeutics |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4671958A (en) * | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
EP0149709B2 (en) * | 1983-07-29 | 1995-11-29 | Milton David Goldenberg | Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles |
JPS60105629A (ja) * | 1983-09-15 | 1985-06-11 | ザ ボ−ド オブ トラステイ−ズ オブ ザ レランド スタンフオ−ド ジユニア ユニバ−シテイ | イムノトキシン |
US4634586A (en) * | 1984-05-21 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Reagent and method for radioimaging leukocytes |
US4735210A (en) * | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US4926869A (en) * | 1986-01-16 | 1990-05-22 | The General Hospital Corporation | Method for the diagnosis and treatment of inflammation |
US4699784A (en) * | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
US4925648A (en) * | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
-
1990
- 1990-10-04 KR KR1019920701323A patent/KR0162259B1/ko not_active IP Right Cessation
- 1990-12-04 ZA ZA909719A patent/ZA909719B/xx unknown
- 1990-12-04 AU AU71666/91A patent/AU646658B2/en not_active Ceased
- 1990-12-04 WO PCT/US1990/006972 patent/WO1991007987A1/en active Application Filing
- 1990-12-04 IL IL9653490A patent/IL96534A/xx not_active IP Right Cessation
- 1990-12-04 CA CA002031129A patent/CA2031129C/en not_active Expired - Fee Related
- 1990-12-04 JP JP3502681A patent/JP2810230B2/ja not_active Expired - Lifetime
- 1990-12-04 IE IE436690A patent/IE65572B1/en not_active IP Right Cessation
- 1990-12-05 AT AT90313175T patent/ATE100719T1/de not_active IP Right Cessation
- 1990-12-05 ES ES90313175T patent/ES2062418T3/es not_active Expired - Lifetime
- 1990-12-05 EP EP90313175A patent/EP0434257B1/en not_active Expired - Lifetime
- 1990-12-05 DE DE69006337T patent/DE69006337T2/de not_active Expired - Fee Related
-
1995
- 1995-06-01 US US08/457,134 patent/US5637288A/en not_active Expired - Lifetime
- 1995-06-01 US US08/457,138 patent/US5677427A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ES2062418T3 (es) | 1994-12-16 |
JP2810230B2 (ja) | 1998-10-15 |
IL96534A0 (en) | 1991-09-16 |
EP0434257A3 (en) | 1991-07-10 |
JPH05502236A (ja) | 1993-04-22 |
CA2031129C (en) | 2000-04-04 |
ZA909719B (en) | 1991-10-30 |
CA2031129A1 (en) | 1991-06-06 |
KR0162259B1 (ko) | 1998-12-01 |
DE69006337T2 (de) | 1994-05-19 |
EP0434257A2 (en) | 1991-06-26 |
AU646658B2 (en) | 1994-03-03 |
US5637288A (en) | 1997-06-10 |
AU7166691A (en) | 1991-06-26 |
US5677427A (en) | 1997-10-14 |
DE69006337D1 (de) | 1994-03-10 |
WO1991007987A1 (en) | 1991-06-13 |
IE65572B1 (en) | 1995-11-01 |
IE904366A1 (en) | 1991-06-05 |
EP0434257B1 (en) | 1994-01-26 |
ATE100719T1 (de) | 1994-02-15 |
IL96534A (en) | 1997-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR927003110A (ko) | 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 카메라 항체 | |
Sharkey et al. | Biodistribution and radiation dose estimates for yttrium-and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts | |
Becker et al. | The use of monoclonal antibodies and antibody fragments in the imaging of infectious lesions | |
US4634586A (en) | Reagent and method for radioimaging leukocytes | |
Breitz et al. | Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin | |
JP2602725B2 (ja) | 多特異抗白血球結合体及び哺乳動物用非経口的注射剤 | |
Kukis et al. | Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates | |
Hens et al. | Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands | |
McAfee et al. | The localization of indium-111-leukocytes, gallium-67-polyclonal IgG and other radioactive agents in acute focal inflammatory lesions | |
US5059413A (en) | Scintigraphic monitoring of immunotoxins using radionuclides and heterobifunctional chelators | |
Buist et al. | Kinetics and tissue distribution of the radiolabeled chimeric monoclonal antibody MOv18 IgG and F (ab′) 2 fragments in ovarian carcinoma patients | |
Choi et al. | Biodistribution of 18F-and 125I-labeled anti-Tac disulfide-stabilized Fv fragments in nude mice with interleukin 2α receptor-positive tumor xenografts | |
van der Laken et al. | Specific targeting of infectious foci with radioiodinated human recombinant interleukin-1 in an experimental model | |
Corstens et al. | Radioimmunoconjugates in the detection of infection and inflammation | |
DeNardo et al. | Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma | |
DePalatis et al. | Lysine reduces renal accumulation of radioactivity associated with injection of the [177Lu] α-[2-(4-aminophenyl) ethyl]-1, 4, 7, 10-tetraaza-cyclodecane-1, 4, 7, 10-tetraacetic acid-CC49 Fab radioimmunoconjugate | |
O'Donnell et al. | 67Copper-2-iminothiolane-6-[p-(bromoacetamido) benzyl]-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma | |
Buchsbaum et al. | Comparative binding and preclinical localization and therapy studies with radiolabeled human chimeric and murine 17-1A monoclonal antibodies | |
Thakur et al. | Technetium-99m-labeled monoclonal antibodies for immunoscintigraphy: simplified preparation and evaluation | |
JP2008540429A (ja) | 癌の治療における併用療法 | |
Thakur et al. | Technetium-99m-labeled proteins for imaging inflammatory foci | |
WO1994004189A1 (en) | Antibody/radioisotope conjugate for tumor diagnosis and/or therapy | |
ES2053403T3 (es) | Diagnosis y tratamiento de la inflamacion. | |
Epstein et al. | Radioimmunodetection of human B-cell lymphomas with a radiolabeled tumor-specific monoclonal antibody (Lym-1) | |
Kobayashi et al. | Repeating the avidin “chase” markedly improved the biodistribution of radiolabelled biotinylated antibodies and promoted the excretion of additional background radioactivity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20050824 Year of fee payment: 8 |
|
LAPS | Lapse due to unpaid annual fee |